Saniona AB has completed preclinical development with SAN-903 and is ready to start the regulatory process for entering phase I trials either alone or together with a partner. SAN-903 is a novel, potential first-in-class medicine based on inhibition of the calcium-activated potassium ion channel KCa3.1.
Chiesi Farmaceutici SpA has synthesized new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Three years after WHO declared the COVID-19 pandemic, some patients are still reporting symptoms from long-ago infections. And the scientific community is studying the reasons for the post-acute sequelae of SARS-CoV-2 (PASC). Until now, the studies provided varied reasons related to persistent COVID or PASC, such as acute SARS-CoV-2 injury in different organs, or reservoirs of the virus in certain tissues, as it happens with other pathogens like HIV. At the IDWeek 2022 infectious disease conference held this week in Washington, D.C., Eric Daar, chief of the Division of HIV Medicine at the Lundquist Institute at Harbor-UCLA Medical Center, moderated the session, 'COVID-19: Post-acute sequelae', where talks offered new results on the symptoms of people who have suffered prolonged COVID during the pandemic.
Chiesi Farmaceutici SpA has described new discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Hpvac SA has announced new data on its lead compound Hpvac-13 for the treatment and prevention of asthmatic attacks in an animal disease model of allergic asthma.
T-cell activation and function depend on Ca2+ signals and Ca2+ influx after antigen binding to the T-cell receptor (TCR) is mediated by store-operated Ca2+ entry (SOCE) through Ca2+ release-activated Ca2+ (CRAC) channels in the plasma membrane.
Chiesi Farmaceutici SpA has patented discoidin domain-containing receptor DDR1 and DDR2 inhibitors reported to be useful for the treatment of fibrosis, particularly idiopathic pulmonary fibrosis (IPF).
Humanwell Healthcare (Group) Co. Ltd. has disclosed G protein-coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of chronic obstructive pulmonary disease, rheumatoid arthritis, inflammatory bowel disease, pulmonary fibrosis, vasculitis, infections, autoimmune and metabolic diseases, among others.
Chiesi Farmaceutici SpA has synthesized Janus kinase inhibitors, particularly JAK1, JAK2, JAK3 and nonreceptor tyrosine-protein kinase TYK2 inhibitors, reported to be useful for the treatment of asthma, chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis and acute respiratory distress syndrome.
RSS
